低剂量依度沙班用于高龄心房颤动患者
ELDERCARE-AF为3期、多中心、随机、双盲、安慰剂对照、事件驱动试验,纳入984例≥80岁日本非瓣膜性房颤患者,均被认为不适合以获批用于卒中预防的剂量进行口服抗凝治疗。患者1:1随机接受依度沙班15 mg每日一次(492例)或安慰剂(492例)。主要疗效终点卒中或体循环栓塞年化率依度沙班组2.3% vs 安慰剂组6.7%(HR 0.34,95%CI 0.19–0.61,P<0.001);主要安全终点大出血年化率3.3% vs 1.8%(HR 1.87,95%CI 0.90–3.89,P=0.09);全因死亡9.9% vs 10.2%(HR 0.97,95%CI 0.69–1.36)。作者结论为在该人群中依度沙班15 mg每日一次在预防卒中或体循环栓塞方面优于安慰剂,且大出血发生率未显著高于安慰剂。
要点
- 人群为≥80岁日本非瓣膜性房颤患者,且被认为不适合以获批用于卒中预防的剂量进行口服抗凝治疗。
- 依度沙班15 mg每日一次较安慰剂显著降低卒中或体循环栓塞年化率(2.3% vs 6.7%,HR 0.34,95%CI 0.19–0.61,P<0.001)。
- 大出血年化率依度沙班组3.3% vs 安慰剂组1.8%(HR 1.87,95%CI 0.90–3.89,P=0.09),未达统计学显著。
- 依度沙班组胃肠道出血事件明显多于安慰剂组。
- 全因死亡两组无显著差异(9.9% vs 10.2%,HR 0.97,95%CI 0.69–1.36)。
适用人群与场景
- ≥80岁日本非瓣膜性房颤患者,且被认为不适合以获批用于卒中预防的剂量进行口服抗凝治疗。
处置流程与药物剂量
- 依度沙班15 mg每日一次口服,用于≥80岁日本非瓣膜性房颤且不适合标准剂量口服抗凝的患者(研究方案剂量)。
研究设计与关键结果
- 3期、多中心、随机、双盲、安慰剂对照、事件驱动试验,纳入984例≥80岁日本非瓣膜性房颤患者,1:1随机接受依度沙班15 mg每日一次(492例)或安慰剂(492例)。
- 主要疗效终点卒中或体循环栓塞年化率:依度沙班组2.3% vs 安慰剂组6.7%(HR 0.34,95%CI 0.19–0.61,P<0.001)。
- 主要安全终点大出血年化率:依度沙班组3.3% vs 安慰剂组1.8%(HR 1.87,95%CI 0.90–3.89,P=0.09)。
- 依度沙班组胃肠道出血事件明显多于安慰剂组。
- 全因死亡:依度沙班组9.9% vs 安慰剂组10.2%(HR 0.97,95%CI 0.69–1.36)。
- 681例完成试验,303例中止(158例退出、135例死亡、10例其他原因),两组中止试验的患者数相似。
证据类型、等级与局限
- 证据类型:3期、多中心、随机、双盲、安慰剂对照、事件驱动试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对≥80岁日本非瓣膜性房颤且被认为不适合标准剂量口服抗凝的患者,依度沙班15 mg每日一次较安慰剂降低卒中或体循环栓塞,大出血未显著增加,但胃肠道出血事件明显更多。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Implementation of appropriate oral anticoagulant treatment for the prevention of stroke in very elderly patients with atrial fibrillation is challenging because of concerns regarding bleeding.
METHODS: We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled, event-driven trial to compare a once-daily 15-mg dose of edoxaban with placebo in elderly Japanese patients (≥80 years of age) with nonvalvular atrial fibrillation who were not considered to be appropriate candidates for oral anticoagulant therapy at doses approved for stroke prevention. The primary efficacy end point was the composite of stroke or systemic embolism, and the primary safety end point was major bleeding according to the definition of the International Society on Thrombosis and Haemostasis.
RESULTS: A total of 984 patients were randomly assigned in a 1:1 ratio to receive a daily dose of 15 mg of edoxaban (492 patients) or placebo (492 patients). A total of 681 patients completed the trial, and 303 discontinued (158 withdrew, 135 died, and 10 had other reasons); the numbers of patients who discontinued the trial were similar in the two groups. The annualized rate of stroke or systemic embolism was 2.3% in the edoxaban group and 6.7% in the placebo group (hazard ratio, 0.34; 95% confidence interval [CI], 0.19 to 0.61; P<0.001), and the annualized rate of major bleeding was 3.3% in the edoxaban group and 1.8% in the placebo group (hazard ratio, 1.87; 95% CI, 0.90 to 3.89; P = 0.09). There were substantially more events of gastrointestinal bleeding in the edoxaban group than in the placebo group. There was no substantial between-group difference in death from any cause (9.9% in the edoxaban group and 10.2% in the placebo group; hazard ratio, 0.97; 95% CI, 0.69 to 1.36).
CONCLUSIONS: In very elderly Japanese patients with nonvalvular atrial fibrillation who were not appropriate candidates for standard doses of oral anticoagulants, a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism and did not result in a significantly higher incidence of major bleeding than placebo. (Funded by Daiichi Sankyo; ELDERCARE-AF ClinicalTrials.gov number, NCT02801669.).
参考来源
- Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med. 2020. PMID: 32865374. doi:10.1056/NEJMoa2012883
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。